Table 2.
Impact of non-invasive tools at week 12 on the risk of endoscopic remission (SES-CD ≤2) at the final visit.
| Univariable analysis |
Multivariable analysis |
|||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Parameters | ||||
| BUSS ≤3.52 | 7.87 (2.71–22.87) | <0.001 | 9.93 (3.10–31.80) | <0.001 |
| Calprotectin μg/g | ||||
| <50 | 3.58 (1.25–10.24) | 0.017 | ||
| <100 | 3.77 (1.21–11.70) | 0.021 | ||
| <250 | 2.93 (0.60–14.14) | 0.17 | ||
| CRP <5 mg/L | 2.66 (0.80–8.87) | 0.11 | ||
| HBI <5 | 1.33 (0.43–4.09) | 0.61 | ||
Abbreviations: SES-CD, Simplified endoscopic activity score for CD; BUSS, Bowel Ultrasound Score; CRP, C-reactive protein; HBI, Harvey-Bradshaw index.
In bold, the significant p-value (p < 0.05 value).